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Pax genes belong to a family of metazoan transcription factors that are known to
play a critical role in eye, ear, kidney and neural development. The mammalian
Pax family of transcription factors is characterized by a 128-amino-acid DNA-
binding paired domain that makes sequence-specific contacts with DNA. The
diversity in Pax gene activities emerges from complex modes of interaction with
enhancer regions and heterodimerization with multiple interaction partners.
Based on in vitro optimal binding-site selection studies and enhancer
identification assays, it has been suggested that Pax proteins may recognize
and bind their target DNA elements with different binding modes/topologies,
however this hypothesis has not yet been structurally explored. One of the most
extensively studied DNA target elements of the Pax6 paired domain is the eye-
lens specific DC5 (-crystallin) enhancer element. In order to shed light on
Pax6–DC5 DNA interactions, the related paired-domain prototype Pax9
was crystallized with the minimal -crystallin DC5 enhancer element and
preliminary X-ray diffraction analysis was attempted. A 3.0 A˚ resolution native
data set was collected at the National Synchrotron Light Source (NSLS),
Brookhaven from crystals grown in a solution consisting of 10%(w/v) PEG 20K,
20%(v/v) PEG 550 MME, 0.03M NaNO3, 0.03M Na2HPO4, 0.03M NH2SO4,
0.1M MES/imidazole pH 6.5. The data set was indexed and merged in space
group C2221, with unit-cell parameters a = 75.74, b = 165.59, c = 70.14 A˚,  =  =
 = 90. The solvent content in the unit cell is consistent with the presence of one
Pax9 paired domain bound to duplex DNA in the asymmetric unit.
1. Introduction
The Pax family of transcription factors (TFs) is characterized by the
presence of an 128-amino-acid paired domain (PD) that is known
to bind DNA in a sequence-specific manner (Noll, 1993). The paired
domain has a bipartite arrangement composed of an N-terminal
subdomain (NTD) and a C-terminal subdomain (CTD) joined by a
linker region (Xu et al., 1999; Balczarek et al., 1997). The Pax proteins
mediate a panoply of functions in haematopoiesis, neurogenesis and
eye development by engaging in alternative DNA-recognition modes
and participating in complex heterodimerization partnerships with
the Sox, Ets and Homeodomain families (Kamachi et al., 2001; Garvie
et al., 2001; Li-Kroeger et al., 2012). Juxtaposition of the optimal Pax6
DNA sequence from in vitroDNA-binding site-selection experiments
with a number of paired-domain responsive DNA sequences reveals
that there are significant deviations in binding-sequence preferences
within the Pax genes (Kamachi et al., 2001; Inoue et al., 2007; Epstein
et al., 1994; Pellizzari et al., 1999).
The crystal structure of the Pax6 PD with the optimal Pax6 binding
site reveals that both the N-terminal and C-terminal domains consist
of three compact -helices, with an additional -hairpin and -turn in
the N-terminal domain (Xu et al., 1999). The third helix of the
N-terminal and C-terminal domains docks against the major groove,
while the linker region makes extensive DNA contacts with the minor
groove. The N-terminal -hairpin makes sugar-phosphate backbone
contacts, while the -turn makes specific base contacts with the minor
groove (Xu et al., 1999). It can be hypothesized that the Pax proteins
recognize alternate DNA sequences through either the use of
different combinations of DNA-binding residues while maintaining a
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similar protein conformation or by binding to the sequences with a
different topology in order to accommodate sequences. Specifically,
we wanted to understand the differential DNA-recognition
mechanism of the Pax6 PD in binding to the eye-lens specific DC5
enhancer element and thus attempted to solve the structure of this
complex. The Pax9 PD exhibits an overall sequence identity of69%
to the Pax6 PD, with a high degree of conservation at the level of
DNA-binding residues, and was thus used as a proxy for the biolo-
gically relevant Pax6, as attempts to crystallize Pax6 with the DC5
DNA resulted in fragile and poor-quality crystals (Fig. 1a).
2. Materials and methods
2.1. Cloning, expression and purification of the Pax9 PD
The Pax9 PD spanning amino acids 4–133 of the full-length mouse
Pax9 protein was PCR-amplified from the Pax9 cDNA (IMAGE
3707718) using primers containing attB and TEV protease cleavage
sites (Table 1). The PCR product was first cloned into pDONR221
(entry vector) and later transferred into pETG40A (destination
vector) encoding an MBP fusion tag using Gateway cloning
(Invitrogen). The pETG40A Pax9 PD expression plasmid was
transformed into competent Escherichia coli BL21 (DE3) cells and
the transformed cells were grown overnight at 37C in LB medium
containing 100 mg ml1 ampicillin. A 10%(v/v) dilution of the over-
night culture was used to inoculate a 5 l LB broth culture at 37C.
When the optical density (OD600) of the culture reached 0.6, the cells
were induced with 0.5 mM IPTG and then grown continuously at
18C overnight. The cells were then pelleted and resuspended in lysis
buffer (40 mM HEPES pH 7.5, 200 mM NaCl, 5 mM -mercapto-
ethanol, 2 mM EDTA) and sonicated on ice for 15 min. Fusion
proteins were extracted from the cell lysate using an amylose column
equilibrated with lysis buffer and eluted with the same buffer
supplemented with 10 mM maltose. The fusion MBP tag was cleaved
using TEV protease at 4C overnight [substrate:TEV ratio of
crystallization communications
1358 Narasimhan et al.  Pax9 paired domain Acta Cryst. (2014). F70, 1357–1361
Table 1
Primers used for cloning and the final amino-acid sequence of the Pax9 PD used for
crystallization.
attB sites are underlined, the TEV cleavage site is italicized and Pax9 sequence-specific
sites are highlighted in bold.
Forward primer 50-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAACCTGT-
ATTTTCAGGGCGCCTTCGGGGAGGTGAACCAGCTG-30
Reverse primer 50-GGGGACCACTTTGTACAAGAAAGCTGGGTTTAGTTGCCGAT-
CTTGTTGCGCAGAATAC-30
Amino-acid sequence of the
construct
GAFGEVNQLGGVFVNGRPLPNAIRLRIVELAQLGIRPCDISRQL-
RVSHGCVSKILARYNETGSILPGAIGGSKPRVTTPTVVKHI-
RTYKQRDPGIFAWEIRDRLLADGVCDKYNVPSVSSISRILR-
NKIGN
Figure 1
(a)Multiple sequence alignment of the Pax9 PD with other mouse Pax family members was carried out using ClustalW. Key amino-acid residues of the paired domain (PD)
involved in major-groove and minor-groove DNA interactions are highlighted using red spheres. (b) EMSAwas carried out with 1 nM 50-FAM-labelled DC5 DNA incubated
with varying concentrations of Pax9 PD. The lowest band in lane 1 corresponds to 1 nM of the free DNAwithout any protein. Protein concentrations increase in a twofold
manner from left to right to a final concentration of 100 nM (lanes 2–9)
100:1(w:w)]. Further purification with a heparin column (GE) was
performed using a linear gradient ranging from 100 mM to 1.0M
NaCl to remove the MBP and TEV fusion tags. Pax9 was eluted and
subjected to a final purification step using HiPrep S-75 gel-filtration
chromatography in gel-filtration buffer (40 mM HEPES pH 7.5,
100 mM NaCl, 5 mM -mercaptoethanol). Pax9 fractions were
concentrated to 100 mM by centrifugation and the purity of the
collected fraction was verified on an SDS–PAGE gel.
2.2. Electrophoretic mobility shift assay (EMSA) of the Pax9 PD with
the DC5 element
The activity of the recombinantly purified Pax9 PD in binding to
the DC5 element was established by EMSA prior to setting up large-
scale crystallization screens. Pax9 PD was titrated at varying
concentrations from 0.78 to 100 nM (in a twofold dilution series) with
1 nM of a fluorescein (FAM)-labelled DC5 DNA element and incu-
bated for 1 h. The samples were then loaded onto a 10% native
polyacrylamide gel and electrophoresis was carried out at 200 V
for 20 min at 4C using a previously established EMSA protocol
(Baburajendran et al., 2011). The gel was subsequently imaged using
a Typhoon phosphorimaging scanner. The forward-strand sequence
of the duplex DC5 DNA used was 50-(FAM)-TTTGTTGCTCACC-
TACCATGGACAAT-30 (the core Pax9 PD binding site is shown in
bold). The Pax9 PD bound to the DC5 DNA element, as confirmed
by the retarded migration of the protein–DNA complex in EMSA
(Fig. 1b).
2.3. Preparation of duplex DC5 DNA for crystallization
Polyacrylamide gel electrophoresis (PAGE)-purified, deprotected
single-stranded DNA oligonucleotides were purchased at 1 mM
concentration predissolved in molecular-grade water (Proligo,
Sigma–Aldrich). Equimolar amounts of complementary DNAs were
mixed and concentrated using a Centricon filter unit (3 kDa
molecular-weight cutoff) into a buffer composed of 40 mM HEPES
pH 7.5, 5 mM -mercaptoethanol, 100 mM NaCl to a final oligo-
nucleotide concentration of 500 mM as measured using a NanoDrop
spectrophotometer. The oligonucleotide mixture was then heated to
95C for 5 min and slowly cooled at a rate of 0.5C min1 to 25C in a
thermocycler and stored at 30C.
2.4. Crystallization
Pax9 PD was mixed with the the DC5_T/A DNA element
containing the core -crystallin binding site in a molar ratio of 1:1.2
and incubated for 1 h on ice. The Pax9 PD–DNA complex was
concentrated using a Centricon filter unit (3 kDa molecular-weight
cutoff) to a final protein concentration of 8 mg ml1 as estimated
using the Bradford reagent. Preliminary high-throughput screening
was carried out with an Innovadyne robot in 96-well sitting-drop
plates using a number of chemical screens from the following
manufacturers: PEG/Ion and Nucleix from Hampton Research, The
PEGs, PEGs II, AmSO4, PACT and JCSG+ Suites from Qiagen,
Morpheus from Molecular Dimensions and JB-NucPro from Jena
Biosciences. The high-throughput sitting-drop screens were carried
out by combining 200 nl protein–DNA complex with 200 nl reservoir
solution over a 50 ml reservoir, with the plates being stored at 18C.
Among the different conditions that were screened, it was observed
that consistently better quality crystals were obtained in many
conditions from Morpheus.
Several optimizations were then performed by the hanging-drop
method around the initial Morpheus hits by varying the DNA
element length and overhangs, the temperature (25, 18 and 4C), the
pH and the salt and PEG constituents. The crystals were harvested
within 2 d, soaked in 15% glycerol as a cryoprotectant for less than 5 s
and flash-cooled in liquid nitrogen for data collection. The final
diffraction-quality crystal from which the complete data set was
collected was obtained by the hanging-drop method in the presence
of 10%(w/v) PEG 20 K, 20%(v/v) PEG 550 MME, 0.03M NaNO3,
0.03M Na2HPO4, 0.03M NH2SO4, 0.1M MES–imidazole pH 6.5 at
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Figure 2
(a) Diamond-shaped rhombic crystals of the Pax9 PD–DC5_T/A complex grown at
18C that gave the best-quality diffraction to 3.0 A˚ resolution. (b) Several crystals
of the Pax9 PD–DC5 DNA complex were washed in reservoir solution, crushed,
dissolved and run on 12% SDS–PAGE stained with SimplyBlue Stain (Invitrogen),
showing a band corresponding to the expected Pax9 PD protein at 14.28 kDa in
lane 2. Lane 1 was loaded with molecular-weight marker (labelled in kDa).
Table 2
Final crystallization conditions.
Method Hanging drop
Plate type EasyXtal 15-Well Tool
Temperature (C) 18
Protein concentration (mg ml1) 8
Buffer composition of protein and
DNA solution
40 mM HEPES pH 7.5, 100 mM NaCl,
5 mM -mercaptoethanol
Volume and ratio of drop 1:1 (1 ml:1 ml)
Volume of reservoir (ml) 500
DNA element† (DC5_T/A) 50-TTTGTTGCTCACCTACCATGGACAAT-30
30-AACAACGAGTGGATGGTACCTGTTAA-50
† The DC5 core recognition site is underlined. Overhangs in the DNA element are
italicized.
18C with the DC5_T/A DNA element (Table 2, Fig. 2a). The
presence of the protein in the crystal was confirmed by analyzing
dissolved crystals using SDS–PAGE as described in Ng et al. (2008)
(Fig. 2b).
2.5. Data collection and processing
The initial X-ray diffraction tests were performed in-house using a
PLATINUM135 CCD detector with focused Cu K X-rays from an
X8 PROTEUM rotating-anode generator (Bruker AXS) controlled
by the PROTEUM2 software (Sheldrick, 2008). The final 3.0 A˚
resolution native data set was collected on the X29A beamline at the
National Synchrotron Light Source (NSLS), Brookhaven. A total
of 360 images were collected with a crystal-to-detector distance of
300 mm, an oscillation angle of 1 and an exposure time of 0.4 s per
image. The data set was integrated, merged and scaled using
the HKL-2000 software (Otwinowski & Minor, 1997). The data-
collection and processing statistics for the Pax9 PD–DC5 complex are
provided in Table 3.
3. Results and discussion
It was observed that the Pax9 PD–DC5 crystals invariably tend to
exhibit anisotropic diffraction with a resolution range of 3–6 A˚ in a
variety of screening conditions. To reduce the anisotropic diffraction,
several combinations of optimization methods such as the Additive
and Silver Bullets Screens (Hampton Research) and crystal-
dehydration methods were undertaken. Crystals grown with additives
and Silver Bullets tended to have sharper edges and grew to slightly
larger than their counterparts. However, this optimization method
failed to significantly reduce the anisotropic diffraction. Crystal
dehydration was carried out under hanging-drop conditions by
increasing the concentration range of the precipitants [10–15%(w/v)
PEG 20K and 20–30%(v/v) PEG 550 MME] in the reservoir. Crystals
dehydrated for longer than 2 h tended to become fragile, while
dehydration for shorter intervals also did not improve the overall
diffraction quality. Flash-annealing by diverting the cryostream for
2–3 s was also unsuccessful. Although many crystallization conditions
were optimized and the resulting crystals tested for diffraction at the
synchrotron, the best crystal still diffracted anisotropically to 3.0 A˚
resolution (Fig. 3).
The Matthews coefficient for the final data set was 3.67 A˚3 Da1,
suggesting a solvent content of 70.06%, assuming that one Pax9 PD
domain is bound to the DC5 enhancer DNA (Matthews, 1968). The
observation of such a relatively high solvent content could be indir-
ectly deduced from the fragile nature of the crystals as well as from
the persistent anisotropic diffraction pattern (Fig. 3). A model
derived from the Pax6 structure (PDB entry 6pax; Xu et al., 1999) was
unsuccessfully used for molecular-replacement trials. It must be noted
that several previous attempts to obtain better diffraction-quality
crystals for the homologous Pax8 and Pax6 paired domains on their
cognate thyroglobulin promoter and LE9 elements have been
unsuccessful as well (Campagnolo et al., 2007; Ito et al., 2005). The
predominant reasons for the difficulty in obtaining better crystals of
Pax8 and Pax6 in the previous studies were proposed to be intrinsic
disorder of the crystalline lattice and anisotropic diffraction,
respectively (Campagnolo et al., 2007; Ito et al., 2005). In the future,
we hope to perform isomorphous replacement with heavy atoms
while also carrying out optimization experiments with a much
broader range of DNA elements to improve the quality of the crystals
and ultimately solve the structure of Pax9 PD with the DC5 enhancer
element.
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